Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Professor Rikard Holmdahl
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Details:
The agreement will support Cyxone to develop their drug candidates T20K and Rabeximod and bring them closer to the market.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
